Omnix Medical

What Omnix Medical does

Omnix Medical Ltd. is a Jerusalem-based, venture-backed clinical-stage biopharmaceutical company founded in 2015 that develops engineered antimicrobial peptides (AMPs) for the treatment of life-threatening infections caused by drug-resistant Gram-negative bacteria. Its proprietary platform produces cyclic peptides derived from the Cecropin family that overcome the two historical barriers to AMP therapeutics — stability and selectivity — by targeting the bacterial membrane itself rather than specific enzymes. This membrane-disrupting mechanism is intended to remain effective against bacteria resistant to last-line treatments such as carbapenems and colistin, and is mechanistically less prone to resistance development.

The company's pipeline centers on three programs: OMN6, a 40-amino acid cyclic peptide in Phase II development for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii (including carbapenem-resistant strains); OMN51, a preclinical-stage AMP targeting MDR Pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis, and COPD patients; and OMN71, aimed at resistant bacteria in skin and topical infections. OMN6 has received both FDA Qualified Infectious Disease Product (QIDP) designation (2018) and FDA Fast-Track designation (2024), and the company has secured a Notice of Allowance from the Indian Patent Office as part of its broader international IP strategy. Phase I data in 80 healthy volunteers demonstrated a favorable safety and pharmacokinetic profile with no severe adverse events up to 300 mg.

Omnix generates no product revenue today and is funded primarily by equity and non-dilutive grants. The company has raised approximately $43 million since inception, most recently a $25 million Series C in October 2025 co-led by Harel Insurance & Finance and the European Innovation Council Fund, with additional support from Entrée Capital, Tal Ventures, Xenia Ventures, Oriella Limited, Prevail Partners, and OurCrowd, plus grants from the EIC Accelerator (€10.8M), the U.S. NIH, and the Israel Innovation Authority. The intended go-to-market model is enterprise B2B distribution via hospital and ICU formularies and procurement channels once OMN6 receives regulatory approval, supplemented in late 2025 by a strategic partnership with Prevail Partners that bundles clinical trial services through Prevail InfoWorks. The company is led by co-founders Dr. Moshik Cohen-Kutner (CEO) and Dr. Niv Bachnoff (CSO), with a headcount in the 11–50 range.

Name

Omnix Medical

Legal name

Omnix Medical Ltd.

Website

https://omnixmedical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Omnix Medical is a Jerusalem-based clinical-stage biopharmaceutical company founded in 2015 that develops engineered antimicrobial peptides targeting life-threatening infections caused by drug-resistant Gram-negative bacteria, with its lead program OMN6 in Phase II for hospital-acquired pneumonia.

Ownership category

akta.pro rank

Product category

Anti-Infective Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Antimicrobial peptides
• Antibiotic drug development
• Drug-resistant bacteria therapeutics
• Hospital-acquired infection treatment
• Biopharmaceutical anti-infectives

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Once regulatory approval is obtained, Omnix Medical will generate revenue through the sale of its antimicrobial peptide therapeutics, initially with OMN6 for resistant bacterial infections. As a biopharmaceutical company developing novel antibiotics, revenue will come from product sales to healthcare systems, hospitals, and through standard pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Omnix Medical develops and commercializes a pipeline of proprietary engineered antimicrobial peptides (AMPs) for the treatment of life-threatening infections caused by drug-resistant bacteria. The lead compound OMN6, a 40-amino acid cyclic peptide derived from Cecropin A, is in Phase II clinical trials for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by carbapenem-resistant Acinetobacter baumannii. Additional pipeline assets OMN51 (targeting MDR Pseudomonas aeruginosa in cystic fibrosis) and OMN71 (skin/topical infections) round out the portfolio.

Product overview

Omnix Medical is a biopharmaceutical company developing a pipeline of novel first-in-class antimicrobial peptides (AMPs) for the treatment of life-threatening infections caused by drug-resistant bacteria. The company's portfolio consists of three main programs: OMN6 (lead compound in Phase II for Acinetobacter baumannii infections), OMN51 (targeting Pseudomonas aeruginosa in cystic fibrosis and bronchiectasis patients), and OMN71 (for skin and topical infections). All three compounds utilize the company's proprietary AMP platform technology, which overcomes the stability and selectivity barriers typically associated with antimicrobial peptides, enabling the creation of degradation-resistant, highly potent cyclic peptide therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• OMN6 OMN6 is a 40-amino acid cyclic antimicrobial peptide (AMP) derived from Cecropin A, designed to treat life-threatening infections caused by carbapenem-resistant Acinetobacter baumannii, including hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). It uses a novel membrane-targeting mechanism of action effective regardless of bacterial genotype or resistance phenotype, and is currently advancing through Phase II clinical trials.
• OMN51 OMN51 is an antimicrobial peptide targeting Gram-negative bacteria, specifically MDR Pseudomonas aeruginosa, which causes recurrent and persistent infections in patients with Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and COPD. Demonstrated rapid bactericidal activity with complete bacterial clearance within 1-8 hours and minimal cytotoxicity.
• OMN71 OMN71 is an antimicrobial peptide targeting bacteria involved in skin and topical indications. Skin infections often involve bacteria with high levels of resistance, making treatment difficult and prolonged. OMN71 is in preclinical development.

Quantifiable outcome

• Rapid bactericidal activity with complete bacterial clearance within 1-8 hours demonstrated for OMN51 against MDR Pseudomonas aeruginosa
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Prevail Partners, LLCcoreStrategic or Co-development Partner · 15 October 2025Strategic and financial partnership announced November 2025. Prevail Partners invests in Omnix Medical and provides clinical trial services through its affiliate Prevail InfoWorks to support development and regulatory approval of OMN6 for resistant bacterial infections.
• Beilinson – Rabin Medical CenterminorStrategic or Co-development PartnerCollaboration with the Adult Cystic Fibrosis and Bronchiectasis Clinic led by Dr. Moshe Heching for testing OMN51 against MDR Pseudomonas aeruginosa isolates from cystic fibrosis patients. Results presented at NACFC and published in peer-reviewed journal.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Entasis Therapeutics: Entasis Therapeutics (an Innoviva subsidiary) is developing antibiotics targeting serious infections caused by MDR Gram-negative bacteria, including durlobactam for A. baumannii—the same priority pathogen Omnix's OMN6 targets. Both companies are specialty antibiotic developers addressing the same unmet need with novel mechanisms.
• VenatoRx Pharmaceuticals: VenatoRx developed cefepime-taniborbactam and other antibiotics for MDR Gram-negative infections, including Pseudomonas and Enterobacterales. Acquired by Innoviva, VenatoRx is one of the most direct comparables in specialty antibiotic development targeting resistant pathogens.
• Iterum Therapeutics: Iterum Therapeutics is a clinical-stage company developing oral antibiotics for MDR infections, including sulopenem. Both companies are specialty antibiotic developers focused on drug-resistant bacterial infections with similar clinical-stage risk profiles.
• Cidara Therapeutics: Cidara Therapeutics develops novel antimicrobial biologics, including Cloudbreak antiviral-antibody conjugates. Both companies leverage biologic approaches (peptides, conjugates) as alternatives to traditional small-molecule antibiotics, addressing drug-resistant infections.
• Spero Therapeutics: Spero Therapeutics is a clinical-stage biopharmaceutical company developing antibiotics for MDR Gram-negative infections, including tebipenem HBr. Spero is a direct peer in the specialty antibiotics space with comparable clinical-stage assets targeting resistant pathogens.
• ContraFect Corporation: ContraFect develops direct lytic agents (lysins) and other antimicrobial biologics for serious infections caused by drug-resistant bacteria, including S. aureus bacteremia. Both companies use biologic modalities as alternatives to traditional antibiotics.
• Nabriva Therapeutics: Nabriva Therapeutics develops antibiotics for serious infections, including lefamulin for community-acquired bacterial pneumonia. Both companies are specialty antibiotic developers with hospital-focused commercialization strategies.

Broad incumbents

• Paratek Pharmaceuticals: Paratek Pharmaceuticals (now part of Gurnet Point) developed and commercialized antibiotics including omadacycline and Nuzyra. As a broader specialty antibiotics company that achieved commercial scale, Paratek represents a more mature incumbent comparable in the antibiotic space.

Others

• Tetraphase Biosciences: Tetraphase developed eravacycline (Xerava) and was acquired by La Jolla Pharmaceutical Company in 2020. Tetraphase is a relevant historical comparable illustrating the development and commercialization journey for novel antibiotics targeting resistant Gram-negative bacteria.
• Melinta Therapeutics: Melinta Therapeutics developed and commercialized multiple antibiotics including delafloxacin and meropenem/vaborbactam before filing for bankruptcy in 2019. Melinta is a cautionary comparable illustrating the commercial challenges facing novel antibiotics developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/MedicalOmnix
• LinkedInlinkedin.com/company/omnix-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omnix Medical